Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aquestive Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AQST
Nasdaq
2834
www.aquestive.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aquestive Therapeutics, Inc.
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
- Feb 12th, 2025 12:00 pm
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
- Feb 4th, 2025 12:00 pm
Institutional investors own a significant stake of 49% in Aquestive Therapeutics, Inc. (NASDAQ:AQST)
- Jan 27th, 2025 10:48 am
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
- Jan 13th, 2025 12:00 pm
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment
- Dec 19th, 2024 4:40 pm
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
- Dec 19th, 2024 1:00 pm
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
- Dec 17th, 2024 6:56 pm
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year
- Dec 17th, 2024 10:42 am
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
- Dec 2nd, 2024 1:00 pm
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?
- Nov 16th, 2024 6:25 am
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- Nov 12th, 2024 1:00 pm
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 6th, 2024 11:13 am
Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
- Nov 6th, 2024 7:07 am
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- Nov 5th, 2024 12:00 am
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
- Nov 4th, 2024 10:50 pm
Aquestive Therapeutics: Q3 Earnings Snapshot
- Nov 4th, 2024 9:48 pm
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 4th, 2024 9:36 pm
Aquestive Therapeutics’ Breakthrough in Allergy Treatment Study
- Oct 25th, 2024 12:29 pm
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting
- Oct 25th, 2024 12:00 pm
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
- Oct 24th, 2024 12:00 pm
Scroll